

IL-10 Protein, Human

Cat. No.:	HY-P7030
Synonyms:	rHuIL-10; CSIF
Species:	Human
Source:	E. coli
Accession:	P22301 (S18-N178)
Gene ID:	3586
Molecular Weight:	Approximately 18.6 kDa

PROPERTIES

AA Sequence	<p> S P G Q G T Q S E N S C T H F P G N L P N M L R D L R D A F S R V K T F F Q M K D Q L D N L L L K E S L L E D F K G Y L G C Q A L S E M I Q F Y L E E V M P Q A E N Q D P D I K A H V N S L G E N L K T L R L R L R R C H R F L P C E N K S K A V E Q V K N A F N K L Q E K G I Y K A M S E F D I F I N Y I E A Y M T M K I R N </p>
Biological Activity	The ED ₅₀ is <1 ng/mL as measured by murine MC/9-2 cells, corresponding to a specific activity of >1.0 × 10 ⁶ units/mg.
Appearance	Lyophilized powder.
Formulation	Lyophilized after extensive dialysis against PBS, pH 7.4.
Endotoxin Level	<1 EU/μg, determined by LAL method.
Reconstitution	It is not recommended to reconstitute to a concentration less than 100 μg/mL in sterile distilled water or aqueous buffer containing 0.1% BSA.
Storage & Stability	Stored at -20°C. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer. It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background	<p>Interleukin 10 (IL-10) is an anti-inflammatory, immunomodulatory cytokine that regulates mucosal inflammation. A promising alternative is interleukin 10 (IL-10), a cytokine with multiple anti-inflammatory and immunoregulatory activities, including inhibition of T-cell/macrophage activation and proinflammatory cytokine synthesis^[1]. IL-10, a cytokine possessing strong anti-inflammatory properties, is under investigation for its therapeutic use as an immunosuppressant. The immunosuppressive actions of IL-10 and corticosteroids include inhibition of proinflammatory cytokine production by monocytes and polymorphonuclear leukocytes (IFN-γ, TNF-α, IL-1β, IL-6, GM-CSF) both at the protein and messenger RNA</p>
------------	--

levels and prevention of mitogen-induced T-cell proliferation^[2].

REFERENCES

- [1]. Fedorak RN, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. *Gastroenterology*. 2000 Dec;119(6):1473-82.
- [2]. Chakraborty A, et al. Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation. *J Pharm Sci*. 2002 May;91(5):1334-42.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA